Rayanna Cadilhe de Oliveira Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rayanna Cadilhe de Oliveira Costa has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Raimunda Sheyla Carneiro Dias
Universidade Federal do Maranhão, Brasil
3 shared publications - Alcione Miranda dos Santos
Federal University of Maranhao
2 shared publications - Ana Karina Teixeira da Cunha França
Universidade Federal do Maranhão, Brazil
2 shared publications - Denizar Vianna Araújo
Universidade do Estado do Rio de Janeiro, Brazil
2 shared publications - Dyego José de Araújo Brito
Universidade Federal do Maranhão, Brazil
2 shared publications - Elton Jonh Freitas Santos
Hospital Universitário da Universidade Federal do Maranhão
2 shared publications
Latest Publications
- Open Access
- 1 November 2020
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 13, 341-348
Correlation Between Parathyroid Hormone Levels with Urinary Magnesium Excretion in Patients with Non-Dialysis Dependent Chronic Kidney Disease
Background: Disorders of mineral metabolism occur in most patients with chronic kidney disease (CKD). The aim of this work was to correlate parathyroid hormone (PTH) levels with urinary magnesium excretion in patients with non-dialysis dependent CKD. Methods: Cross-sectional study. Concentrations of creatinine, magnesium, calcium, phosphate, parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D] and alkaline phosphatase (ALP) were determined in blood samples. The assessment of urinary magnesium levels was performed by means of total daily excretion and by the excretion fraction (FEMg). Results: The study evaluated 163 patients with a mean age of 60.7 ± 11.7 years and 51.0% were male. In the highest quartile of PTH (> 89.5pg/mL), the mean levels of FEMg and ALP were higher (p< 0.05). In the unadjusted regression analysis, the following variables were related to serum PTH levels: FEMg (odds ratio (OR) = 1.12; 95% confidence intervals (CI): 1.02– 1.23), calcium (OR = 0.45; 95% CI: 0.22– 0.90), ALP (OR = 1.02; 95% CI: 1.00– 1.03) and eGFR (OR = 0.92; 95% CI: 1.00– 1.03). After an adjusted analysis, only one FEMg and ALP will remain correlated with PTH. Conclusion: In patients with non-dialysis dependent CKD, FEMg and ALP were some variables that remained associated with PTH.
- 1 November 2020
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 13, 341-348
Open AccessCorrelation Between Parathyroid Hormone Levels with Urinary Magnesium Excretion in Patients with Non-Dialysis Dependent Chronic Kidney Disease
Background: Disorders of mineral metabolism occur in most patients with chronic kidney disease (CKD). The aim of this work was to correlate parathyroid hormone (PTH) levels with urinary magnesium excretion in patients with non-dialysis dependent CKD. Methods: Cross-sectional study. Concentrations of creatinine, magnesium, calcium, phosphate, parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D] and alkaline phosphatase (ALP) were determined in blood samples. The assessment of urinary magnesium levels was performed by means of total daily excretion and by the excretion fraction (FEMg). Results: The study evaluated 163 patients with a mean age of 60.7 ± 11.7 years and 51.0% were male. In the highest quartile of PTH (> 89.5pg/mL), the mean levels of FEMg and ALP were higher (p< 0.05). In the unadjusted regression analysis, the following variables were related to serum PTH levels: FEMg (odds ratio (OR) = 1.12; 95% confidence intervals (CI): 1.02– 1.23), calcium (OR = 0.45; 95% CI: 0.22– 0.90), ALP (OR = 1.02; 95% CI: 1.00– 1.03) and eGFR (OR = 0.92; 95% CI: 1.00– 1.03). After an adjusted analysis, only one FEMg and ALP will remain correlated with PTH. Conclusion: In patients with non-dialysis dependent CKD, FEMg and ALP were some variables that remained associated with PTH.
- Open Access
- 1 September 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (9) , 1235-1240
Prevalence of sarcopenia in kidney transplants and their association with determinant factors of muscle homeostasis
SUMMARY INTRODUCTION: Sarcopenia is characterized by the involuntary loss of lean body mass associated with a progressive reduction of muscle strength. OBJECTIVE: To determine the prevalence of sarcopenia in kidney transplant recipients and its association with the determining factors that control muscle homeostasis. METHODS: We evaluated renal transplant recipients undergoing follow-up at the University Hospital of the Federal University of Maranhão from June 2017 to July 2018 and who met the inclusion criteria. Sarcopenia was defined according to the European criteria. The skeletal muscle mass index was measured by dual-energy radiological absorptiometry; the values <7,26 kg/m2 for men and <5,5 kg/m2 for women were adopted for muscle depletion. For handgrip strength, values of <30 kg for men and <20 kg for women were considered as reduced muscle strength. In both sexes, the cutoff point for walking speed was <0,8 m/s. RESULTS: We evaluated 83 renal transplant recipients with a mean age of 48.8 ± 12,1 years and predominantly males (57,8%). The prevalence of sarcopenia was 19,3%. Among individuals without sarcopenia, 17,9% had a decrease in handgrip strength and 40,3% has altered gait speed. DISCUSSION: Individuals submitted to renal transplant may develop sarcopenia while still young and already present altered muscle function and strength even before the depletion of lean body mass. CONCLUSION: Early diagnosis may allow the prevention of sarcopenia and provide a better quality of life for patients.
- 1 September 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (9) , 1235-1240
Open AccessPrevalence of sarcopenia in kidney transplants and their association with determinant factors of muscle homeostasis
SUMMARY INTRODUCTION: Sarcopenia is characterized by the involuntary loss of lean body mass associated with a progressive reduction of muscle strength. OBJECTIVE: To determine the prevalence of sarcopenia in kidney transplant recipients and its association with the determining factors that control muscle homeostasis. METHODS: We evaluated renal transplant recipients undergoing follow-up at the University Hospital of the Federal University of Maranhão from June 2017 to July 2018 and who met the inclusion criteria. Sarcopenia was defined according to the European criteria. The skeletal muscle mass index was measured by dual-energy radiological absorptiometry; the values <7,26 kg/m2 for men and <5,5 kg/m2 for women were adopted for muscle depletion. For handgrip strength, values of <30 kg for men and <20 kg for women were considered as reduced muscle strength. In both sexes, the cutoff point for walking speed was <0,8 m/s. RESULTS: We evaluated 83 renal transplant recipients with a mean age of 48.8 ± 12,1 years and predominantly males (57,8%). The prevalence of sarcopenia was 19,3%. Among individuals without sarcopenia, 17,9% had a decrease in handgrip strength and 40,3% has altered gait speed. DISCUSSION: Individuals submitted to renal transplant may develop sarcopenia while still young and already present altered muscle function and strength even before the depletion of lean body mass. CONCLUSION: Early diagnosis may allow the prevention of sarcopenia and provide a better quality of life for patients.
- Open Access
- 22 August 2020
- Published by Springer Nature in Research Square
Correlation Between Serum Parathormone Levels With Urinary Magnesium Excretion In Patients With Non-Dialytic Chronic Kidney Disease
Background: Disorders of mineral metabolism occur in most patients with chronic kidney disease (CKD). The aim of this work was to correlate serum parathyroid hormone (PTH) levels with urinary magnesium excretion in patients with non-dialysis CKD.Methods: Cross-sectional study with patients with CKD undergoing non-dialysis treatment in stages 3A, 3B and 4. Concentrations of creatinine, magnesium, calcium, phosphorus, parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D] and alkaline phosphatase (ALP) were determined in blood samples. The assessment of urinary magnesium levels was performed by means of total daily excretion and by the excretion fraction (FEMg). Results: The study evaluated 163 patients with a mean age of 60.7 ± 11.7 years and 51.0% were male. In the highest quartile of PTH (> 89.5pg / ml), the mean levels of FEMg and ALP were higher (p <0.05), as well as the levels of serum calcium and eGFR were lower (p <0.05). In the unadjusted regression analysis, the following variables were related to serum PTH levels: FEMg (odds ratio (OR) = 1.12; 95% confidence intervals (CI): 1.02–1.23), Calcium (OR = 0.45; 95% CI: 0.22-0.90), ALP (OR = 1.02; 95% CI: 1.00-1.03) and eTFG (OR = 0.92; 95% CI: 1.00-1.03). After an adjusted analysis, only one FEMg and ALP will remain correlated with PTH. Conclusion: In patients with non-dialysis CKD, with higher levels of PTH, higher mean columns of ALP and FEMg, and lower levels of serum calcium and eGFR. FEMg and ALP were some variables that remained associated with PTH.
- 22 August 2020
- Published by Springer Nature in Research Square
Open AccessCorrelation Between Serum Parathormone Levels With Urinary Magnesium Excretion In Patients With Non-Dialytic Chronic Kidney Disease
Background: Disorders of mineral metabolism occur in most patients with chronic kidney disease (CKD). The aim of this work was to correlate serum parathyroid hormone (PTH) levels with urinary magnesium excretion in patients with non-dialysis CKD.Methods: Cross-sectional study with patients with CKD undergoing non-dialysis treatment in stages 3A, 3B and 4. Concentrations of creatinine, magnesium, calcium, phosphorus, parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D] and alkaline phosphatase (ALP) were determined in blood samples. The assessment of urinary magnesium levels was performed by means of total daily excretion and by the excretion fraction (FEMg). Results: The study evaluated 163 patients with a mean age of 60.7 ± 11.7 years and 51.0% were male. In the highest quartile of PTH (> 89.5pg / ml), the mean levels of FEMg and ALP were higher (p <0.05), as well as the levels of serum calcium and eGFR were lower (p <0.05). In the unadjusted regression analysis, the following variables were related to serum PTH levels: FEMg (odds ratio (OR) = 1.12; 95% confidence intervals (CI): 1.02–1.23), Calcium (OR = 0.45; 95% CI: 0.22-0.90), ALP (OR = 1.02; 95% CI: 1.00-1.03) and eTFG (OR = 0.92; 95% CI: 1.00-1.03). After an adjusted analysis, only one FEMg and ALP will remain correlated with PTH. Conclusion: In patients with non-dialysis CKD, with higher levels of PTH, higher mean columns of ALP and FEMg, and lower levels of serum calcium and eGFR. FEMg and ALP were some variables that remained associated with PTH.
- Open Access
- 1 January 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (2) , e145922143
Fatores de risco para hiperglicemia em pacientes transplantados renais
O objetivo desse estudo foi analisar os fatores de risco associados com a hiperglicemia em pacientes transplantados renais. Para tanto, foi realizado um estudo transversal retrospectivo com coleta de dados clínicos, laboratoriais e antropométricos de pacientes que realizaram transplante renal. Para identificar fatores associados à hiperglicemia, foi realizada análise bivariada e multivariada com modelos hierarquizados. Dentre os 89 pacientes avaliados, o índice de massa corporal revelou 47,1% dos pacientes eutróficos e 34,7% com excesso de peso. Observou-se que 28% dos pacientes apresentavam hiperglicemia e 82%, 86,5%, 87,6% e 91% tinham creatinina, ureia, hemoglobina, e hematócrito alterados, respectivamente. Foi encontrada associação estatística significativa (p<0,05) de hiperglicemia com obesidade II e III, e pacientes com obesidade II e III tinham mais chances de ter glicemia e potássio alterados, (RP=4,91; IC: 1,04, p<0,001; RP=2,23; IC: 1,09-4,54, p=0,026), respectivamente. Verificou-se que a obesidade e a hipercalemia foram fatores de risco para a hiperglicemia em pacientes transplantados renais.
- 1 January 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (2) , e145922143
Open AccessFatores de risco para hiperglicemia em pacientes transplantados renais
O objetivo desse estudo foi analisar os fatores de risco associados com a hiperglicemia em pacientes transplantados renais. Para tanto, foi realizado um estudo transversal retrospectivo com coleta de dados clínicos, laboratoriais e antropométricos de pacientes que realizaram transplante renal. Para identificar fatores associados à hiperglicemia, foi realizada análise bivariada e multivariada com modelos hierarquizados. Dentre os 89 pacientes avaliados, o índice de massa corporal revelou 47,1% dos pacientes eutróficos e 34,7% com excesso de peso. Observou-se que 28% dos pacientes apresentavam hiperglicemia e 82%, 86,5%, 87,6% e 91% tinham creatinina, ureia, hemoglobina, e hematócrito alterados, respectivamente. Foi encontrada associação estatística significativa (p<0,05) de hiperglicemia com obesidade II e III, e pacientes com obesidade II e III tinham mais chances de ter glicemia e potássio alterados, (RP=4,91; IC: 1,04, p<0,001; RP=2,23; IC: 1,09-4,54, p=0,026), respectivamente. Verificou-se que a obesidade e a hipercalemia foram fatores de risco para a hiperglicemia em pacientes transplantados renais.